Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Cyclerion Therapeutics (CYCN) Leases (2019 - 2023)

Cyclerion Therapeutics (CYCN) has disclosed Leases for 5 consecutive years, with $1.1 million as the latest value for Q2 2023.

  • For Q2 2023, Leases fell 14.12% year-over-year to $1.1 million; the TTM value through Jun 2023 reached $1.1 million, down 14.12%, while the annual FY2022 figure was $1.2 million, 13.12% down from the prior year.
  • Leases hit $1.1 million in Q2 2023 for Cyclerion Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Leases topped out at $70.3 million in Q2 2019 and bottomed at $1.1 million in Q2 2023.
  • Average Leases over 5 years is $26.9 million, with a median of $6.3 million recorded in 2021.
  • On a YoY basis, Leases climbed as much as 12.77% in 2022 and fell as far as 96.8% in 2022.
  • Cyclerion Therapeutics' Leases stood at $68.1 million in 2019, then tumbled by 36.3% to $43.4 million in 2020, then crashed by 96.77% to $1.4 million in 2021, then fell by 13.12% to $1.2 million in 2022, then dropped by 7.64% to $1.1 million in 2023.
  • According to Business Quant data, Leases over the past three periods came in at $1.1 million, $1.2 million, and $1.2 million for Q2 2023, Q1 2023, and Q4 2022 respectively.